Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models. (December 2016) - O'Connor, M.J.; Odedra, R.; Palakurthi, S.; Hughes, A.; Lai, Z.; Kirschmeier, P.; Zeng, Q.; Zhou, S.; Dharma, S.; Ivanova, E.; Wang, A.; Pierce, A.J.; et al.